联合CIK 细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta 分析.docVIP

联合CIK细胞与化疗对比单纯化疗治疗 中晚期非小细胞肺癌的Meta分析 罗虎 罗丹 宫亮 周向东(第三军医大学西南医院呼吸内科重庆 400038（通讯作者：周向东，E-mail:xiangdongzhou@126.com）Pubmed、EMBASE、Cochrane LibrarCochrane Handbook 5.0的质量评价标准，用RevMan 5.0软件进行统计学分析。结果 共纳入6项临床研究，789例患者，eta分析R734.2 Meta-analysis of chemotherapy in combination with CIK cells verus chemotherapy in the Treatment of NSCLC LUO Hu, LUO Dan, GONG Liang, ZHOU Xiangdong(Department of Respiratory Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038,China) [Abstract] Background and objective Chemotherapy in combination with CIK cells is a new alternative for patients with advanced non-small cell lung cancer (NSCLC), but whether this kind of method is superior to simple chemotherapy remains unclear. The aim of this study is to evaluate the efficacy and safety of chemotherapy in combination with CIK cells verus chemotherapy in the Treatment of NSCLC. Methods We searched relevant clinical researches from Pubmed, EMBASE, Cochrane Library, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Chinese Scientific Journals Full-text Database, then we performed a meta-analysis according to the quality evaluation criteria provided by Cochrane Handbook 5.0 with software RevMan 5.0. Results Six clinical studies including 460 patients were identified. There were significant statistical differences between two groups in efficiency （OR=1.72，95%CI:1.17-2.52）,Kamofsky score（OR=4.26, 95%CI:1.90-9.58）and median survival time(MST),but there were no statistical differences one-year survival rate（OR=1.48, 95%CI:0.97-2.25）and side effects including neutropenia（OR=0.63,95%CI:0.26-1.49）, gastrointestinal reactions (OR=0.87,95%CI:0.47-1.60),hepatotoxicity(OR=1.24,95%CI:0.57-2.69）and anemia （OR=0.76,95%CI:0.31-1.90）,but fever and headache were reported more often during the CIK infusion. Conclusion Compared to simple chemotherapy, combined CIK cells and chemotherapy were superior in clinical efficacy, Kamofsky score and MST, while there were no